For the Inventor, By the Inventor

Enter assignee name

Planegg-Martinsried, Germany

4sc Ag

USPTO Granted Patents = 52

CIPO Patents = 12

EPO Patents = 15

Trademarks = 3

Forward Citations = 380

Loading Chart...

Loading Chart...

76 inventors (with patents filed for the assignee):

Thomas Beckers (19 out of 36 patents)

Thomas Maier (17 out of 45 patents)

Johann Leban (12 out of 17 patents)

4. Thomas Baer (10 out of 13 patents)

5. Petra Gimmnich (9 out of 9 patents)

6. Mathias Schmidt (9 out of 9 patents)

7. Stefan Tasler (8 out of 11 patents)

8. Volker Gekeler (8 out of 12 patents)

9. Thomas Bär (8 out of 11 patents)

10. Astrid Zimmermann (8 out of 14 patents)

11. Klaus Pekari (8 out of 8 patents)

12. Matthias Vennemann (7 out of 11 patents)

13. Stefano Pegoraro (6 out of 6 patents)

14. Daniel Vitt (5 out of 13 patents)

15. Kristina Wolf (5 out of 5 patents)

Core Competencies:

HDAC Inhibitors

CD137 Agonists

KV1.3 Inhibitors

DYRK Kinase Inhibitors

Sulfonylpyrroles

Indolopyridines

Tetrahydropyridothiophenes

Heterocyclic NF-kB Inhibitors

Anti-inflammatory Agents

Benzazole Analogues

Cancer Therapy

Immunomodulatory Compounds

52 patents: Sort by Forward Citations

1. 12285410 - Combination comprising HDAC inhibitor and CD137 agonist for cancer therapy (2025-04-29),

2. 10822345 - KV1.3 inhibitors and their medical application (2020-11-03),

3. 10723743 - Kv1.3 inhibitors and their medical application (2020-07-28),

4. 10633369 - Method of inhibiting DYRK1B (2020-04-28),

5. 10399991 - Kv1.3 inhibitors and their medical applications (2019-09-03),

6. 10005769 - 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors (2018-06-26),

7. 9951050 - Method of inhibiting DYRK1B (2018-04-24),

8. 9908880 - Substituted imidazoquinolines (2018-03-06),

9. 9446040 - Substituted imidazoquinolines (2016-09-20),

10. 9073913 - Substituted imidazoquinolines (2015-07-07),

11. 8969401 - Sulfonylpyrroles (2015-03-03),

12. 8815855 - N-sulphonylpyrroles and their use as histone deacetylase inhibitors (2014-08-26),

13. 8785659 - Method for the production of sulphonylpyrroles as HDAC inhibitors (2014-07-22),

14. 8575193 - N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds (2013-11-05),

15. 8557991 - Process for preparing enantiomerically pure indolopyridines (2013-10-15),

4SC AG is a clinical-stage biopharmaceutical company focused on the development of small molecule drugs for the treatment of cancer. The company's core drug candidates target various cancer indications, including solid tumors and hematological cancers. 4SC AG utilizes its proprietary discovery platform to identify and develop potential therapeutic compounds. With a focus on personalized medicine, 4SC AG aims to provide innovative treatment options for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

52 Patents

#1 in Planegg-Martinsried

#1,047 in Germany

#13,160 in the World

Planegg-Martinsried, Germany

4sc Ag

Forward Citations = 380

76 inventors:

Thomas Beckers (19 out of 36 patents)

Thomas Maier (17 out of 45 patents)

Johann Leban (12 out of 17 patents)

4. Thomas Baer (10 out of 13 patents)

5. Petra Gimmnich (9 out of 9 patents)

Please report any incorrect information to support@idiyas.com

Loading…